Stay updated with breaking news from Hookipa Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Royal Bank of Canada reissued their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a report published on Tuesday morning, Benzinga reports. The firm currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their target price on shares of Hookipa Pharma from $6.50 to $5.00 and set […]
Royal Bank of Canada reaffirmed their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $5.00 price target on the stock. Separately, HC Wainwright reduced their price target on shares of Hookipa Pharma from […]
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority...